[Depressive syndromes within the scope of schizophrenic diseases].
The results of a standardized examination of 135 schizophrenics shows that the "depressive factor" is less pronounced during differential neuroleptic therapy (Clozapin, Haloperidol) and in the control group of schizophrenics receiving no drug treatment. This suggests that the depressive syndrome among schizophrenics is not manifested as a result of pharmaceutical action. The author proposes that neuroleptic therapy tailored to the patient can ameliorate the depressive syndrome observed in schizophrenics. Both psychoreactive and disease specific factors may play a role in the pathogenesis of depression among patients with this disease.
D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D003866:Depressive Disorder / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology*; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D012306:Risk; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
D003024:Clozapine; D006220:Haloperidol
Zur Problematik depressiver Syndrome im Rahmen schizophrener Erkrankungen.